Question explored with the scientific record
Are travel vaccines effective?
Travel vaccines are a mixed bag: some work well for specific diseases in specific people, but the evidence is thinner than most travelers are told.
The retrieved studies show real protection for a few vaccines. The oral cholera vaccine Vaxchora showed 90% efficacy at 10 days and 80% at 90 days in a small challenge trial of 66 adults [5]. The yellow fever vaccine produces protective antibodies in over 90% of recipients, though serious adverse events rise with age: about 6.5 per 100,000 doses in people aged 60-69 and 10.3 per 100,000 in those 70 and older [4, 6]. The new dengue vaccine TAK-003 showed 81% efficacy against all serotypes in people already exposed to dengue, and cut hospitalization by 97%, but its benefit in travelers who have never had dengue is uncertain, and no data exists for adults over 60 [4].
Other vaccines have weaker or more conditional evidence. The typhoid Vi vaccine showed 74% efficacy in a Nepalese field trial, but only 23% efficacy in travelers to India [2]. The ETEC (traveler's diarrhea) vaccine never hit its primary endpoint in a phase 3 trial; only a post-hoc reanalysis suggested protection against more severe cases [1]. The rabies pre-exposure vaccine simplifies post-exposure care but is expensive, and the cost to prevent one rabies death through wide pre-exposure vaccination was estimated at over $5 million [3].
The evidence is also shaped by who paid for it. The cholera, dengue, and ETEC trials were funded by the manufacturers [1, 5]. Many studies use antibody levels as a stand-in for real protection, not hard outcomes like hospitalization or death [4, 6, 7]. Long-term safety data beyond a few years is absent for most travel vaccines.
My call: a few travel vaccines (yellow fever for younger adults, cholera for high-risk settings, dengue for previously infected travelers) have real but conditional benefit. Most others have weak or conflicted evidence. Confidence: moderate for the vaccines with field trials, low for the rest.
Sources used 7
-
Efficacy of an Enterotoxigenic Escherichia coli (ETEC) Vaccine on the Incidence and Severity of Traveler’s Diarrhea (TD): Evaluation of Alternative Endpoints and a TD Severity Score
A reanalysis of the OEV-118 Phase 3 enterotoxigenic Escherichia coli (ETEC) vaccine trial using alternative clinical endpoints and a traveler’s diarrhea (TD) severity score to better quantify vaccine impact, showing protection against more severe ETEC TD and suggesting TD scorin…
DOI: 10.3390/microorganisms11102414 -
Typhoid and paratyphoid fever in travellers
This study reviews the epidemiology, clinical features, treatment, and vaccine efficacy of enteric fever, particularly focusing on the impact of travel to endemic regions and the rising antibiotic resistance of Salmonella typhi and Salmonella paratyphi.
DOI: 10.1016/s1473-3099(05)70239-5 -
Preexposure Rabies Vaccination
An evidence-based discussion of the rationale, availability, efficacy, safety, and cost-effectiveness of preexposure rabies vaccination for travelers and at-risk individuals, arguing that while it can simplify postexposure management, it is expensive and not universally indicate…
DOI: 10.1111/j.1708-8305.1994.tb00556.x -
Travel vaccination in senior travelers: current evidence, challenges, and prevention
Vaccination in senior travelers should be individualized and exposure-based, prioritizing routine vaccines while weighing yellow fever and emerging dengue/chikungunya vaccines against age-specific risks; age-specific evidence remains limited.
DOI: 10.1186/s40794-026-00315-1 -
Vaxchora: A Single-Dose Oral Cholera Vaccine
This study reviews the efficacy and safety of Vaxchora, a single-dose oral cholera vaccine, demonstrating 90.3% protection against cholera caused by Vibrio cholerae serogroup O1 in adults traveling to cholera-affected areas.
DOI: 10.1177/1060028017698162 -
Yellow fever vaccines and international travelers
A comprehensive review of yellow fever epidemiology, the indications for vaccination in international travelers, vaccine safety and adverse events, regulatory changes, vaccine supply, and future developments in yellow fever vaccines.
DOI: 10.1586/14760584.7.5.579 -
A new inactivated Japanese encephalitis vaccine for adult travelers
This study evaluates the safety and immunogenicity of a new inactivated Japanese encephalitis vaccine produced in Vero cells, demonstrating its non-inferiority to the existing mouse brain-derived vaccine and suggesting a reassessment of vaccination guidelines for travelers.
DOI: 10.1016/j.tmaid.2009.03.009